Acne Keloidalis Nuchae Clinical Trial
Official title:
Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN)
Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoid combination approved by the FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii for the management of early-mild AKN. The research team hypothesizes that subjects will experience significant clinical improvement in lesion counts. Patients will be followed with visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits, there will be surveys regarding the severity of AKN symptoms, photographs, and clinical assessments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00757315 -
NdYag Laser for Acne Keloidalis Nuchae
|
N/A | |
| Completed |
NCT02372786 -
7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream
|
Phase 4 | |
| Completed |
NCT01548898 -
The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study
|
Phase 4 | |
| Terminated |
NCT00476697 -
UVA1 Light for Scleroderma and Similar Conditions
|
N/A | |
| Completed |
NCT01328080 -
Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy
|
N/A |